业绩方面，华昊中天至今并未实现盈利，公司2022年、2023年营收分别为3282万元、6664万元(单位为人民币，下同)，期内亏损分别为1.61亿元、1.9亿元。2024年前5个月，公司营收为2856万元，较上年同期增长5.58%，经营亏损为5743万元，较上年同期缩窄31.14%。Huahao Zhongtian Pharmaceutical-B (02563) plummeted by more than 37%. The stock was listed on October 31 this year and closed up 30% on the same day. Since then, the stock price has been rising steadily. As of press release, it decreased by 37.18% to HK$19.82, with a turnover of HK$11.9471 million.
The Zhitong Finance App learned that Huahao Zhongtian Pharmaceutical-B (02563) plummeted by more than 37%. The stock was listed on October 31 this year and closed up 30% on the same day. Since then, the stock price has been rising steadily. As of press release, it decreased by 37.18% to HK$19.82, with a turnover of HK$11.9471 million.
According to reports, Huahao Zhongtian was founded in 2002 and is a biomedical company driven by synthetic biology technology, dedicated to developing innovative cancer drugs. When the company's core product was approved for marketing by the State Drug Administration in 2021, the average sales price was 2388.71 yuan/bottle. It was included in the national medical insurance drug catalogue in 2022. The negotiated price officially came into effect on March 1, 2023, and the price of this product dropped by more than 60%. However, thanks to the amount of medical insurance, the company's product sales have increased accordingly in recent years.
In terms of performance, Huahao Zhongtian has not achieved profit so far. The company's revenue for 2022 and 2023 was 32.82 million yuan and 66.64 million yuan (unit is RMB, same below), and losses for the period were 0.161 billion yuan and 0.19 billion yuan respectively. In the first five months of 2024, the company's revenue was 28.56 million yuan, up 5.58% from the same period last year, and operating loss was 57.43 million yuan, down 31.14% from the same period last year.
